BioNTech

Prezzo: 90.54

Società e modello di business

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Its core products include mRNA-based vaccines, notably the COVID-19 vaccine developed in partnership with Pfizer. Major business segments encompass vaccine development, oncology therapies, and research collaborations. The primary revenue source has been from vaccine sales, particularly during the pandemic, although recent financial reports indicate a significant decline in revenue.

Profilo di investimento

The investment profile of BioNTech is more aligned with growth investors, given its focus on innovative therapies and potential for future product development. However, the recent decline in revenue and negative earnings per share suggest increased risk, making it less suitable for conservative investors. The stock may appeal to those with a higher risk tolerance looking for long-term growth opportunities.

Sito ufficiale

Metriche fondamentali (sperimentale)

EPS (TTM) — utile per azione degli ultimi 12 mesi, $: -5.09 Rischio
Ricavi QoQ — crescita dei ricavi trimestre su trimestre: -86.6% ↓
Sorpresa EPS: 3.7% in linea
Volatilità 20g: 1.9% stabile

Dati FMP / FinFeed aggiornati: 2026-06-11

Impatto della previsione

neutrale

Rating migliorato · UBS · valido fino a 2026-06-26 · aggiornato 2026-06-13

Target +49.1% raggiungimento target 67.1%

Reazione D5 -1.67% · D10 -5.82%

Impatto Potenziale 0 · Rischio 0 fino a 30 giorni o finché il target non viene raggiunto

Racc.: Vendi Potenziale: 30 Rischio: 73 Aggiornato: 2026-06-13 02:36

Come funziona la raccomandazione

Perché l'AI la pensa così:

Weak fundamentals and negative momentum raise significant concerns.

Traccia in portafoglio

Grafico prezzo

Raccomandazione AI Previsione analista Evento calendario Segnale positivo Segnale negativo Neutrale / aggiornamento Mantieni / informativo B My buy S My sell

Cambiamenti di raccomandazione AI

Data	Prima	Dopo	Motivo
2026-05-12 02:57	Mantieni	Vendi	scenario_deterioration
2026-05-08 15:29	—	Mantieni	Weak fundamentals and negative momentum signal high risk.
2026-05-08 05:27	Mantieni	Mantieni	Компания демонстрирует значительное снижение выручки и отрицательный EPS, что указывает на финансовые трудности. Текущие тренды и высокая волатильность делают инвестиции в BioNTech рискованными.
2026-04-17 02:54	Vendi	Mantieni	Компания испытывает значительное снижение выручки и отрицательный EPS, что указывает на высокие риски. Однако недавний рост цены акций может свидетельствовать о восстановлении интереса инвесторов.
2026-03-22 07:36	Mantieni	Vendi	scenario_deterioration
2026-03-11 05:26	—	Mantieni	Компания испытывает значительное падение цен на акции и нестабильность в финансовых показателях, что указывает на высокие риски для инвесторов.

Previsioni analisti

Data	Analista	Action	Target	Prezzo allora
2026-05-27 08:43	UBS	Rating migliorato	— → 135	92.25
2026-05-21 20:24	Bernstein	Aggiorna	— → 96	90.93
2026-05-06 11:32	Canaccord Genuity	Target abbassato	171 → 158	95.5
2026-04-10 12:55	Morgan Stanley	Target alzato	125 → 126	93.381
2026-03-11 13:15	BMO Capital	Target abbassato	— → 128	90.52
2026-03-10 19:41	Jefferies	Target abbassato	— → 138	83.89
2026-03-10 18:28	Truist Financial	Aggiorna	— → 155	83.89
2026-03-10 16:29	Morgan Stanley	Target abbassato	— → 128	83.89
2026-02-02 11:03	Leerink Partners	Rating peggiorato	— → 113	113.75
2026-01-16 11:49	Goldman Sachs	Rating migliorato	— → 142	106.07
2025-12-11 17:03	Berenberg Bank	Target alzato	150 → 155	95.68
2025-12-11 11:43	H.C. Wainwright	Aggiorna	— → 140	96.91
2025-11-03 19:21	Morgan Stanley	Target alzato	131 → 134	103.955

Ancora nulla